Progress of research on prognosis evaluation methods in IgA nephropathy

doi:10.3877/cma.j.issn.2095-3216.2017.05.010

Abstract

Abstract:

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Although it is a chronic progressive disease, the prognosis of individuals varies greatly. Therefore, the prognosis assessment and the end-point event prediction have been hot issues of study. At present, the prognosis-assessing methods of IgAN mainly include pathological classification (Lee′s classification, Oxford classification, etc), clinical indicators (baseline proteinuria, eGFR, etc), mathematical models (ARR score, GOTO model), and biomarkers (urinary TGF-β1, IL-6, etc). A variety of methods provides means for the early prediction and intervention of IgAN prognosis, but each method has its advantages and disadvantages, of which recent research progress was reviewed in this article.

Key words: IgA nephropathy, Prognosis, Pathology, Clinical indicator, Biomarker

Jian Liu, Shuwei Duan, Xiangmei Chen. Progress of research on prognosis evaluation methods in IgA nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(05): 233-238.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2017.05.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/233

References 73

[1]	Berger J, Hinglais N. Intercapillary deposits of IgA-IgG [J]. J Urol Nephrol (Paris), 1968, 74(9): 694-695.
[2]	Lee H, Hwang JH, Paik JH, et al. Long-term prognosis of clinically early IgA nephropathy is not always favorable [J]. BMC Nephrol, 2014, 15: 94.
[3]	Moriyama T, Tanaka K, Iwasaki C, et al. Prognosis in IgA nephropathy: 30-year analysis of 1，012 patients at a single center in Japan [J]. PLoS One, 2014, 9(3): e91756.
[4]	Tomino Y. Predictors of prognosis in IgA nephropathy [J]. Kaohsiung J Med Sci, 2012, 28(10): 517-520.
[5]	Tomino Y. Immunopathological predictors of prognosis in IgA nephropathy [J]. Contrib Nephrol, 2013, 181: 65-74.
[6]	Frimat L, Briançon S, Hestin D, et al. IgA nephropathy: prognostic classification of end-stage renal failure. L′Association des Néphrologues de l'Est [J]. Nephrol Dial Transplant, 1997, 12(12): 2569-2575.
[7]	Ibels LS, Györy AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature [J]. Medicine (Baltimore), 1994，73(2): 79-102.
[8]	Shimizu A, Takei T, Moriyama T, et al. Clinical and pathological studies of IgA nephropathy presenting as a rapidly progressive form of glomerulonephritis [J]. Intern Med, 2013, 52(22): 2489-2494.
[9]	Sato R, Joh K, Komatsuda A, et al. Validation of the Japanese histologic classification 2013 of immunoglobulin A nephropathy for prediction of long-term prognosis in a Japanese single-center cohort [J]. Clin Exp Nephrol, 2015, 19(3): 411-418.
[10]	Bellur SS, Lepeytre F, Vorobyeva O, et al. Evidence from the Oxford classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy [J]. Kidney Int, 2017, 91(1): 235-243.
[11]	Lee SM, Rao VM, Franklin WA, et al. IgA nephropathy: morphologic predictors of progressive renal disease [J]. Hum Pathol, 1982, 13(4): 314-322.
[12]	Meadow SR, Glasgow EF, White RH, et al. Schönlein-Henoch nephritis [J]. Perspect Nephrol Hypertens, 1973, 1 Pt2(0): 1089-1104.
[13]	Lee HS, Lee MS, Lee SM, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H．S. Lee′s glomerular grading system [J]. Nephrol Dial Transplant, 2005, 20(2): 342-348.
[14]	Bogenschütz O, Bohle A, Batz C, et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients [J]. Am J Nephrol, 1990, 10(2): 137-147.
[15]	D′Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors [J]. Am J Kidney Dis, 2000, 36(2): 227-237.
[16]	Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases [J]. Am J Kidney Dis, 1997, 29(6): 829-842.
[17]	Tan M, Li W, Zou G, et al. Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria [J]. Kidney Blood Press Res, 2015, 40(2): 200-206.
[18]	Haas M, Reich HN. Morphologic markers of progressive immunoglobulin A nephropathy [J]. Adv Chronic Kidney Dis, 2012, 19(2): 107-113.
[19]	Katafuchi R, Kiyoshi Y, Oh Y, et al. Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation [J]. Clin Nephrol, 1998, 49(1): 1-8.
[20]	Liu Y, Hu Q, Shen P, et al. Clinical and pathological analysis of IgA nephropathy with chronic renal failure[J]. Ren Fail, 2016，38(9): 1347-1352.
[21]	Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification [J]. Kidney Int, 2009, 76(5): 534-545.
[22]	Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility [J]. Kidney Int, 2009, 76(5): 546-556.
[23]	Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group [J]. Kidney Int, 2017, 91(5): 1014-1021.
[24]	Markowitz G. Glomerular disease: updated Oxford classification of IgA nephropathy: a new MEST-C score [J]. Nat Rev Nephrol, 2017, 13(7): 385-386.
[25]	Ştefan G, Ismail G, Stancu S, et al. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining [J]. Pathol Int, 2016, 66(8): 453-459.
[26]	Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments [J]. Kidney Int, 2014, 86(4): 828-836.
[27]	Le W, Zeng CH, Liu Z, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China [J]. BMC Nephrol, 2012, 13: 158.
[28]	Zhang W, Zhou Q, Hong L, et al. Clinical outcomes of IgA nephropathy patients with different proportions of crescents [J]. Medicine (Baltimore), 2017, 96(11): e6190.
[29]	Shao X, Li B, Cao L, et al. Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis [J]. Oncotarget, 2017, 8(28): 46436-46448.
[30]	Lv J, Shi S, Xu D, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis [J]. Am J Kidney Dis, 2013, 62(5): 891-899.
[31]	Park KS, Han SH, Kie JH, et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy [J]. Hum Pathol, 2014, 45(2): 236-243.
[32]	Gutiérrez E, Zamora I, Ballarín JA, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria [J]. J Am Soc Nephrol, 2012, 23(10): 1753-1760.
[33]	Radford MG, Donadio JV, Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy [J]. J Am Soc Nephrol, 1997, 8(2): 199-207.
[34]	Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population [J]. Nephrol Dial Transplant, 2012, 27(4): 1479-1485.
[35]	Zittema D, van den Brand JA, Bakker SJ, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients [J]. Nephrol Dial Transplant, 2017, 32(Suppl 1): i146-i153.
[36]	Zhang JJ, Yu GZ, Zheng ZH, et al. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy [J]. PLoS One, 2017, 12(4): e0175828.
[37]	Lv J, Zhang H, Zhou Y, et al. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China [J]. Nephrology (Carlton), 2008, 13(3): 242-246.
[38]	Okonogi H, Utsunomiya Y, Miyazaki Y, et al. A predictive clinical grading system for immunoglobulin A nephropathy by combining proteinuria and estimated glomerular filtration rate [J]. Nephron Clin Pract, 2011, 118(3): c292-c300.
[39]	Wakai K, Kawamura T, Endoh M, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study [J]. Nephrol Dial Transplant, 2006, 21(10): 2800-2808.
[40]	Ni Z, Yuan Y, Wang Q, et al. Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission [J]. J Transl Med, 2014, 12: 194.
[41]	Ohno I, Hosoya T, Gomi H, et al. Serum uric acid and renal prognosis in patients with IgA nephropathy [J]. Nephron, 2001, 87(4): 333-339.
[42]	Cheng GY, Liu DW, Zhang N, et al. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up [J]. Clin Nephrol, 2013, 80(1): 40-46.
[43]	Skrzypczyk P, Mizerska-Wasiak M, Jerszow B, et al. Ambulatory arterial stiffness index, blood pressure variability, and nocturnal blood pressure dip in children with IgA and Henoch-Schönlein nephropathy [J]. Clin Nephrol, 2017, 87(6): 301-309.
[44]	Jarrick S, Lundberg S, Welander A, et al. Clinical validation of immunoglobulin A nephropathy diagnosis in Swedish biopsy registers [J]. Clin Epidemiol, 2017, 9: 67-73.
[45]	Tomino Y. Diagnosis and treatment of patients with IgA nephropathy in Japan [J]. Kidney Res Clin Pract, 2016, 35(4): 197-203.
[46]	Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis [J]. Ann Intern Med, 2003, 139(4): 244-252.
[47]	Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy [J]. J Am Soc Nephrol, 2011, 22(4): 752-761.
[48]	Konishi Y, Nishiyama A, Morikawa T, et al. Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy [J]. Hypertension, 2011, 58(2): 205-211.
[49]	Mertens PR, Floege J. IgA-nephropathy: the most common type of glomerulonephritis [J]. Dtsch Med Wochenschr, 2003, 128(22): 1242-1246.
[50]	陈仆，陈香美，谢院生，等．不同性别原发性IgA肾病随增龄的临床病理特点[J]．中国中西医结合肾脏病杂志，2008，9(5): 413-416.
[51]	Goto M, Kawamura T, Wakai K, et al. Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm [J]. Nephrol Dial Transplant, 2009, 24(4): 1242-1247.
[52]	Le W, Liang S, Chen H, et al. Long-term outcome of IgA nephropathy patients with recurrent macroscopic hematuria [J]. Am J Nephrol, 2014, 40(1): 43-50.
[53]	Delclaux C, Jacquot C, Callard P, et al. Acute reversible renal failure with macroscopic haematuria in IgA nephropathy [J]. Nephrol Dial Transplant, 1993, 8(3): 195-199.
[54]	吕继成，陈育青，王海燕．家族性IgA肾病- 777例中国IgA肾病回顾性调查分析[J]．中华肾脏病杂志，2004，(01): 5-7.
[55]	Izzi C, Ravani P, Torres D, et al. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression [J]. Am J Kidney Dis, 2006, 47(5): 761-769.
[56]	Tanaka S, Ninomiya T, Katafuchi R, et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2013, 8(12): 2082-2090.
[57]	Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan [J]. Am J Kidney Dis, 2009, 53(6): 982-992.
[58]	Sakai H, Abe K, Kobayashi Y, et al. Clinical guidelines of IgA nephropathy [J]. Nihon Jinzo Gakkai Shi, 1995, 37(8): 417-421.
[59]	Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study [J]. Nephrol Dial Transplant, 2009, 24(10): 3068-3074.
[60]	Knoop T, Vågane AM, Vikse BE, et al. Addition of eGFR and age improves the prognostic absolute renal risk-model in 1，134 Norwegian patients with IgA nephropathy [J]. Am J Nephrol, 2015, 41(3): 210-219.
[61]	Berthoux F, Mariat C, Maillard N. Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy [J]. Nephrol Dial Transplant, 2013, 28(Suppl 4): iv160-iv166.
[62]	Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score [J]. PLoS One, 2012, 7(6): e38904.
[63]	Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression [J]. Kidney Int, 2012, 82(7): 790-796.
[64]	Zhang J, Wang C, Tang Y, et al. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy [J]. Nephrology (Carlton), 2013, 18(2): 125-131.
[65]	Robert T, Berthelot L, Cambier A, et al. Molecular insights into the pathogenesis of IgA nephropathy [J]. Trends Mol Med, 2015, 21(12): 762-775.
[66]	Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy [J]. J Am Soc Nephrol, 2012, 23(9): 1579-1587.
[67]	Harada K, Akai Y, Kurumatani N, et al. Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study [J]. Nephron, 2002, 92(4): 824-826.
[68]	Stangou M, Papagianni A, Bantis C, et al. Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine [J]. Clin Nephrol, 2013, 80(3): 203-210.
[69]	Lundberg S, Lundahl J, Gunnarsson I, et al. Soluble interleukin-2 receptor alfa predicts renal outcome in IgA nephropathy [J]. Nephrol Dial Transplant, 2012, 27(5): 1916-1923.
[70]	Torres DD, Rossini M, Manno C, et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy [J]. Kidney Int, 2008, 73(3): 327-333.
[71]	Worawichawong S, Radinahamed P, Muntham D, et al. Urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as biomarkers for interstitial fibrosis and tubular atrophy in primary glomerulonephritis [J]. Kidney Blood Press Res, 2016, 41(6): 997-1007.
[72]	Urushihara M, Nagai T, Kinoshita Y, et al. Changes in urinary angiotensinogen posttreatment in pediatric IgA nephropathy patients [J]. Pediatr Nephrol, 2015, 30(6): 975-982.
[73]	Wang J, Liang M, Xu J, et al. Renal expression of advanced oxidative protein products predicts progression of renal fibrosis in patients with IgA nephropathy [J]. Lab Invest, 2014, 94(9): 966-977.

Please choose a citation manager

Content to export